Figures & data
Figure 1 Timing of VAS, USS and POMS relative to MIP.
![Figure 1 Timing of VAS, USS and POMS relative to MIP.](/cms/asset/5d75a985-fc2b-45d9-8095-89ec2908e846/dndt_a_172334_f0001_c.jpg)
Table 1 Demographic and clinical characteristics
Figure 2 Significant increase in VAS depressed mood scores after the sad MIP during supplement (mean ± SD: 1.56±2.09 cm, t[20]=3.43) and Placebo (mean ± SD: 1.12±1.81 cm, t[20]=2.84) but no effect of dietary supplement in reducing vulnerability to sad mood after sad MIP compared to placebo (rmANOVA: F[1,19]=0.56, P=0.47).
![Figure 2 Significant increase in VAS depressed mood scores after the sad MIP during supplement (mean ± SD: 1.56±2.09 cm, t[20]=3.43) and Placebo (mean ± SD: 1.12±1.81 cm, t[20]=2.84) but no effect of dietary supplement in reducing vulnerability to sad mood after sad MIP compared to placebo (rmANOVA: F[1,19]=0.56, P=0.47).](/cms/asset/768ea9cf-84a8-4b4e-865e-1dc0a4f600dd/dndt_a_172334_f0002_b.jpg)
Figure 3 Significant increase in USS scores after sad MIP during supplement (mean ± SD: 0.63±0.83, t[20]=3.50) and placebo (mean ± SD: 0.45±0.68, t[20]=3.04) with no differences between the groups for change in USS scores (rmANOVA: F[1,19]=0.72, P=0.41).
![Figure 3 Significant increase in USS scores after sad MIP during supplement (mean ± SD: 0.63±0.83, t[20]=3.50) and placebo (mean ± SD: 0.45±0.68, t[20]=3.04) with no differences between the groups for change in USS scores (rmANOVA: F[1,19]=0.72, P=0.41).](/cms/asset/873f9e2d-6efe-4fa8-be7e-0ad9f522b318/dndt_a_172334_f0003_b.jpg)
Figure 4 Significant correlation between the change in VAS depressed mood scores on both active study visits (Pearson r=0.57, P=0.007, R2=0.32). B (degree of slope) in regression is 0.54.
![Figure 4 Significant correlation between the change in VAS depressed mood scores on both active study visits (Pearson r=0.57, P=0.007, R2=0.32). B (degree of slope) in regression is 0.54.](/cms/asset/727103e6-a6e4-44f4-a053-8514813c7960/dndt_a_172334_f0004_b.jpg)
Figure S1 Visual analog scale (VAS) mood scores in subjects receiving active dietary supplement and placebo. The sad mood induction procedure was done between time points 4 and 5. (Time points correspond to: 1=7:35 am, 2=8:40 am, 3=10:10 am, 4=11:20 am, 5=12.25 pm, 6=13:10 am, 7=14:30) (Data shown as mean and standard error).
![Figure S1 Visual analog scale (VAS) mood scores in subjects receiving active dietary supplement and placebo. The sad mood induction procedure was done between time points 4 and 5. (Time points correspond to: 1=7:35 am, 2=8:40 am, 3=10:10 am, 4=11:20 am, 5=12.25 pm, 6=13:10 am, 7=14:30) (Data shown as mean and standard error).](/cms/asset/0057cf35-46a5-4b6f-a267-7b071602e0f3/dndt_a_172334_sf0001_b.jpg)
Figure S2 Urge to smoke scale (USS) scores in subjects receiving active dietary supplement and placebo. The sad mood induction procedure was done between time points 3 and 4. (Time points correspond to: 1=7:35 am, 2=8:40 am, 3=11:20 am, 4=12.25 pm, 5=14:30 pm) (Data shown as mean and standard error).
![Figure S2 Urge to smoke scale (USS) scores in subjects receiving active dietary supplement and placebo. The sad mood induction procedure was done between time points 3 and 4. (Time points correspond to: 1=7:35 am, 2=8:40 am, 3=11:20 am, 4=12.25 pm, 5=14:30 pm) (Data shown as mean and standard error).](/cms/asset/29d2f415-7e06-474f-a21f-b82460934607/dndt_a_172334_sf0002_b.jpg)
Figure S3 Significant increase in profile-of-mood-state (POMS) scale depression/dejection score after sad mood induction procedure (MIP) during supplement (mean ± SD: 2.95±4.57, t[20]=2.95, P=0.008) and placebo (mean ± SD: 2.19±3.37, t[20]=2.98, P=0.007), but no effect of dietary supplement in reducing vulnerability to sad MIP compared to placebo conditions (F[1,19]=0.002, P=0.97).
![Figure S3 Significant increase in profile-of-mood-state (POMS) scale depression/dejection score after sad mood induction procedure (MIP) during supplement (mean ± SD: 2.95±4.57, t[20]=2.95, P=0.008) and placebo (mean ± SD: 2.19±3.37, t[20]=2.98, P=0.007), but no effect of dietary supplement in reducing vulnerability to sad MIP compared to placebo conditions (F[1,19]=0.002, P=0.97).](/cms/asset/6f5fa356-1f59-4aeb-abc6-4daa70e01823/dndt_a_172334_sf0003_b.jpg)